164 related articles for article (PubMed ID: 11131964)
21. [Study of the susceptibility of Staphylococcus sp. and Enterococcus sp. to teicoplanin and vancomycin].
Mimica I; Mendes CM; Mimica L; Oplustil C; Pignatari AC; Sader H
Rev Assoc Med Bras (1992); 1996; 42(3):147-50. PubMed ID: 9138356
[TBL] [Abstract][Full Text] [Related]
22. Resistance to vancomycin and teicoplanin: an emerging clinical problem.
Johnson AP; Uttley AH; Woodford N; George RC
Clin Microbiol Rev; 1990 Jul; 3(3):280-91. PubMed ID: 2143434
[TBL] [Abstract][Full Text] [Related]
23. In vitro susceptibility of Staphylococci and Enterococci to vancomycin and teicoplanin.
Guzek A; Korzeniewski K; Nitsch-Osuch A; Rybicki Z; Prokop E
Adv Exp Med Biol; 2013; 788():125-32. PubMed ID: 23835969
[TBL] [Abstract][Full Text] [Related]
24. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
25. Glycopeptide resistance in coagulase-negative staphylococci.
Biavasco F; Vignaroli C; Varaldo PE
Eur J Clin Microbiol Infect Dis; 2000 Jun; 19(6):403-17. PubMed ID: 10947214
[TBL] [Abstract][Full Text] [Related]
26. [The invitro activity of teicoplanin and vancomycin against gram positive microorganisms (corrected)].
Kayaokay Y; Hasçelik G; Gür D; Akalin E
Mikrobiyol Bul; 1991 Oct; 25(4):321-5. PubMed ID: 1839050
[TBL] [Abstract][Full Text] [Related]
27. [A comparative microbiological and pharmacokinetic activity of vancomycin and teicoplanin].
Cohen R; Barre J; Varon E
Pathol Biol (Paris); 1992 Oct; 40(8):831-44. PubMed ID: 1484744
[TBL] [Abstract][Full Text] [Related]
28. Microbiological properties of teicoplanin.
Greenwood D
J Antimicrob Chemother; 1988 Jan; 21 Suppl A():1-13. PubMed ID: 2965119
[TBL] [Abstract][Full Text] [Related]
29. Mono and double modified teicoplanin aglycon derivatives on the amino acid no. 7; structure-activity relationship.
Pavlov AY; Preobrazhenskaya MN; Malabarba A; Ciabatti R; Colombo L
J Antibiot (Tokyo); 1998 Jan; 51(1):73-8. PubMed ID: 9531990
[TBL] [Abstract][Full Text] [Related]
30. Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
Printsevskaya SS; Pavlov AY; Olsufyeva EN; Mirchink EP; Preobrazhenskaya MN
J Med Chem; 2003 Mar; 46(7):1204-9. PubMed ID: 12646030
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of the new glycopeptide decaplanin.
Neu HC; Chin NX; Niu WW
Eur J Clin Microbiol Infect Dis; 1992 May; 11(5):458-62. PubMed ID: 1330562
[TBL] [Abstract][Full Text] [Related]
32. Comparative in vitro activity of teicoplanin and vancomycin against United States teicoplanin clinical trial isolates of gram-positive cocci.
Kenny MT; Dulworth JK; Brackman MA
Diagn Microbiol Infect Dis; 1991; 14(1):29-31. PubMed ID: 1826479
[TBL] [Abstract][Full Text] [Related]
33. [Activity of vancomycin, teicoplanin and linezolid in methicillin resistant coagulase-negative Staphylococci isolates from paediatric blood cultures].
Fajardo Olivares M; Hidalgo Orozco R; Rodríguez Garrido S; Gaona Álvarez C; Sánchez Silos RM; Hernández Rastrollo R; Martínez Tallo E; Cordero Carrasco JL
Rev Esp Quimioter; 2012 Mar; 25(1):25-30. PubMed ID: 22488538
[TBL] [Abstract][Full Text] [Related]
34. Rapid detection and differentiation method of VanA, VanB and VanC phenotypes in vancomycin-resistant enterococci.
Hanaki H; Yamaguchi Y; Nomura S; Nagayama A; Sunakawa K
Int J Antimicrob Agents; 2004 May; 23(5):502-5. PubMed ID: 15120731
[TBL] [Abstract][Full Text] [Related]
35. Glycopeptide resistance in enterococci.
Méndez-Alvarez S; Pérez-Hernández X; Claverie-Martín F
Int Microbiol; 2000 Jun; 3(2):71-80. PubMed ID: 11001535
[TBL] [Abstract][Full Text] [Related]
36. [Bacterial resistance to vancomycin and other glycopeptide antibiotics: an emerging threat].
Kłoszewska M; Markiewicz Z
Postepy Biochem; 1999; 45(2):122-36. PubMed ID: 10581636
[No Abstract] [Full Text] [Related]
37. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
Fraise AP; Andrews J; Wise R
J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
[TBL] [Abstract][Full Text] [Related]
38. [Antimicrobial spectrum of dalbavancin. Mechanism of action and in vitro activity against Gram-positive microorganisms].
Cercenado E
Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():9-14. PubMed ID: 28129822
[TBL] [Abstract][Full Text] [Related]
39. Enterococcal-type glycopeptide resistance genes in non-enterococcal organisms.
Patel R
FEMS Microbiol Lett; 2000 Apr; 185(1):1-7. PubMed ID: 10731599
[TBL] [Abstract][Full Text] [Related]
40. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
Jones RN; Fritsche TR; Sader HS; Goldstein BP
J Chemother; 2005 Dec; 17(6):593-600. PubMed ID: 16433188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
